Bin Y Zeng

US Patent:

6838256, Jan 4, 2005

Filed:

Dec 13, 2000

Appl. No.:

09/734672

Inventors:

Patricia D. Murphy - Slingerland NY, US
Antonette C. Allen - Severn MD, US
Christopher P. Alvares - Potomac MD, US
Brenda S. Critz - Frederick MD, US
Sheri J. Olson - Arlington VA, US
Denise B. Schelter - Silver Spring MD, US
Bin Zeng - Rockville MD, US

Assignee:

Gene Logic Inc. - Gaithersburg MD

International Classification:

C12P 2106
C12N 500
C12N 1500
C12N 1563
C07H 2102

US Classification:

435 691, 4253201, 425325, 425455, 4252521, 425471, 536 231, 536 235

Abstract:

isolated coding sequences and to the protein sequences they code for. This invention is directed to three coding sequence of the BRCA1 gene. The three coding sequences, BRCA1, BRCA1, and BRCA1and their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences.

US Patent:

56541554, Aug 5, 1997

Filed:

Feb 12, 1996

Appl. No.:

8/598591

Inventors:

Patricia D. Murphy - Slingerland NY
Antonette C. Allen - Millersville MD
Christopher P. Alvares - Potomac MD
Brenda S. Critz - Frederick MD
Sheri J. Olson - Arlington VA
Denise B. Schelter - Burtonsville MD
Bin Zeng - Rockville MD

Assignee:

OncorMed, Inc. - Gaithersburg MD

International Classification:

C12Q 168
C12P 1934
C07H 2104
C07H 2102

US Classification:

435 6

Abstract:

A consensus DNA sequence has been determined for the BRCA1 gene. As has been seven polymorphic sites and their rates of occurrence in normal BRCA1 genes. The consensus gene BRCA1. sup. (omi) and the seven polymorphic sites will provide greater accuracy and reliability for genetic testing. One skilled in the art will be better able to avoid misinterpretations of changes in the gene, determine the presence of a normal gene, and of mutations, and to classify tumors.

US Patent:

57504008, May 12, 1998

Filed:

Feb 12, 1997

Appl. No.:

8/798691

Inventors:

Patricia D. Murphy - Slingerland NY
Antonette C. Allen - Severn MD
Christopher P. Alvares - Potomac MD
Brenda S. Critz - Frederick MD
Sheri J. Olson - Arlington VA
Denise B. Schelter - Silver Spring MD
Bin Zeng - Rockville MD

Assignee:

OncorMed, Inc. - Gaithersburg MD

International Classification:

C12Q 168
C12P 1934
C07H 2104
C07H 2102

US Classification:

435 6

Abstract:

This invention is directed to three coding sequences of the BRCA1 gene. The three coding sequences, BRCA1. sup. (omi1), BRCA1. sup. (omi2) and BRCA1. sup. (omi3) as well as their frequencies of occurrence are provided together with the protein sequences they code for. Another aspect of this invention is a method of determining the consensus sequence for any gene. Another aspect of the invention is a method of identifying an individual having an increased genetic susceptibility to breast or ovarian cancer because they have inherited a causative mutation in their BRCA1 gene. This invention is also related to a method of performing gene therapy with any of the isolated BRCA1 coding sequences.